PTC Therapeutics

Ahead of International PKU Day, we’re spotlighting mental health in the PKU community. Kevin, Signe & Regina share their journeys with stigma, anxiety & resilience. Learn more about their stories: ow.ly/YqMQ50ZbgLL

Our 2025 Corporate Social Responsibility Report highlights a year of focus, execution and measurable progress delivering differentiated medicines for people with rare disorders. See how we're driving impact across access, innovation, people & our planet: ow.ly/gwTR50Z6RRt

On #ClinicalTrialsDay, we honor patients, families, and clinical teams advancing rare disease research. This year's #ResearchRising theme reminds us that progress comes from partnership and trust. Learn more: ow.ly/wJiY50Z1Ml5

May is Friedreich’s ataxia (FA) Awareness Month and we're proud to honor the strength of those living with this rare condition. Kailey’s journey reflects the challenges many face, from recognizing symptoms to finding support. Learn more: ow.ly/KkRx50YZAmQ

Some days, the hardest part of living with a rare disorder isn’t what others can see—it’s the uncertainty: navigating genetic testing barriers and painful life changes. During #HDAwarenessMonth, PTC is proud to share stories like April's. Learn more: ow.ly/F1os50YWhRo

Today, we announced our Q1 2026 financial results, highlighting record performance and continued momentum across the business—led by the global launch of our treatment for #PKU. See the release: ow.ly/lbyh50YWi0T and webcast recording: ow.ly/5l7u50YWi1B

PTC will participate in three upcoming investor conferences in May and June. Learn more: ow.ly/sGsN50YVbXo

This #NationalPKUAwarenessMonth, we’re honoring the resilience of the PKU community. Living with PKU is more than a diet—it takes constant planning, advocacy and support. Amanda’s story, alongside her mom Jill, helps make the invisible visible. Learn more: ow.ly/kfKX50YTBSG

On Rare Disease Day, we recognize the millions living with rare conditions. At PTC, we know that progress starts with listening to those impacted. Together, we can make a difference. Learn more: ow.ly/pwXK50YliIh

PTC will participate in three upcoming investor conferences in March, including TD Cowen 46th Annual Health Care Conference, Leerink 2026 Global Healthcare Conference and the Barclays Global Healthcare Conference. Learn more: ow.ly/PEC450YmECC

PKU is rare—but the PKU community’s strength is extraordinary. Living with PKU means daily planning, monitoring, and resilience. This Rare Disease Day, we’re amplifying their voices. Watch, listen, and share their stories: ow.ly/3sAY50Yj1Zg

Today, we announced our Q4 and full-year 2025 financial results, highlighting strong revenue performance that sets the stage for continued growth and innovation in the coming year. Learn more in our release: ow.ly/QStt50Yirls and webcast recording: ow.ly/2aOO50Yiq6Y

Proud to stand with the global #RareDisease community and families impacted by AADC deficiency (#AADCd). As Dr. Marcus Wheeler notes, symptoms can overlap with other disorders—so awareness matters. We’re committed to providing education, support, and earlier recognition.

PTC was honored to receive BioNJ's 2026 Innovator Award for the FDA approval of our treatment for PKU. Thank you, BioNJ, and congrats to everyone advancing the future of medicine.

Sometimes, the right opportunity finds you. Luke Millington turned his internship at PTC into a career supporting the #DMD community. Read his inspiring story: ow.ly/Amcu50YavHM

PTC will host a web conference call to report our fourth-quarter and full-year 2025 financial results and provide an update on the company’s business on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. Learn more: ow.ly/nNs950Y9i0G

At PTC, our commitment to those with significant unmet medical needs drives us every day. In honor of Rare Disease Day this month, we're sharing the story of Tiffany, a mother of two living with #FA, a rare, neuromuscular disorder. Learn more: ow.ly/HZyr50Y6o3M.

Pam and Kelsey are helping to raise awareness of phenylketonuria (PKU) by sharing their inspiring story. Read more: ow.ly/3xa950Y4yxJ

#ICYMI: At the J.P. Morgan 2026 Healthcare Conference, PTC Therapeutics shared key updates on our strong positioning for success in 2026 and beyond. Learn more: ow.ly/UZhU50XXA8h

Today, our CEO Dr. Matthew Klein, shared highlights from a successful 2025 and an outlook for what we expect to be an exciting 2026 at the J.P. Morgan Healthcare Conference. Learn more: ow.ly/Q8gR50XVF8L